长寿转变：医生参与长寿医学的新纪元

A New Era of PhysicianEngagement in LongevityMedicine Pelin Tozan For physicians, this creates a real challenge.Many find themselves in unfamiliar territory,trying to answer questions about various“health maximizing” methods, while stillmanaging their regular patient load. Thetraditional dynamic of the doctor-patientrelationship may be shifting in ways that createnew complexity for both parties. educational and scientific requirements of afundamentally preventive discipline. It’s aboutprevention, optimization, and helping healthypeople stay healthy longer. That requires adifferent kind of engagement strategy - onebuilt on education, scientific credibility, andlong-term relationship-building. Executive summary •Wellness‑driven patients are changing physician‑patient dynamics by bringing newdata, expectations, and longevity‑focused questions into the consultation.•Many physicians are interested in longevity medicine but face barriers aroundevidence, reimbursement, and education, especially when treating “healthy”individuals preventively.•Companies entering the space will need education‑led, multi‑stakeholderengagement strategies – grounded in robust science and tailored to differenthealth‑system realities. Longevity medicine is gaining momentum,but many companies are still unsure how toengage physicians in ways that truly resonate.Those who get it right will shape the futureof the space. In this paper, we explore wherephysicians stand today, what’s holding themback, and how companies can build trusted,lasting partnerships that drive value forproviders, businesses, and ultimately, patients. But here’s the thing: the playbooks that workedin traditional therapeutic areas are unlikelyto work here without significant adaptation.Standard commercial and medical modelswere largely designed around treating existingconditions – a paradigm that may not fully alignwith longevity medicine’s focus. Longevitymedicine flips that script entirely. It demandsengagement strategies aligned with the researched online, inquiring about whather “biological age” actually indicates, andexploring how she can maximize her healthyyears. A meaningful shift is taking place in clinicalsettings across the healthcare landscape,and it’s worth paying attention to. In our previous piece, “The Longevity Shift:Strategic Implications of the LongevityMedicine Revolution”, we exploredhow longevity is reshaping pipelines,portfolios, and value creation for lifesciences companies. This paper builds onthat foundation by focusing on a criticalquestion: how physicians are engaging withlongevity medicine - and what that means forcompanies entering the space? This scenario, once relatively rare, is becomingincreasingly commonplace. The wellness-driven patient population appears to beevolving, with many proactively seekinginformation beyond traditional clinicalchannels. The traditional dynamicof the doctor-patientrelationship may beshifting in ways thatcreate new complexityfor both parties. We’re witnessing the emergence of whatwe might call the “wellness-driven patient”:individuals who are no longer content toengage with medicine only when somethinggoes wrong. These patients may arrive withquestions that fall outside typical clinicalconversations, data from consumer devices,results from wellness or risk assessment tests,and expectations that could extend beyond thetraditional annual physical. They’re thinkingabout healthspan - how long they stay healthy,active, and independent, rather than justlifespan – how long they live. Consider this potential scenario: A wellness-driven patient arrives for her annual check-up. Before her physician even pulls up herchart, she presents months of continuousglucose data from her wearable device,sleep architecture trends from her smartring, and heart rate variability patterns she’sbeen monitoring consistently. She isn’t therebecause something is wrong. She’s there tooptimize her health trajectory. She’s askinginformed questions about supplements she In practice, when physicians evaluate thislandscape, they see something different. Theysee research conducted primarily in laboratorysettings, early-stage human trials with limitedpopulations, and findings that, while intriguing,don’t yet meet the evidentiary standardsthey were trained to require before makingprescribing decisions. The large-scale, long-term clinical trials that physicians typically relyon for prescribing confidence may still be inprogress or on the horizon for many longevity-related interventions. The evidence gap Understanding the physician’s perspective For physicians considering engagementwith longevity medicine, the current state ofevidence poses a practical challenge worthunderstanding. Before we can build effective partnershipswith the physician community, we must firstdevelop a nuanced appreciation for wherethey stand today. The reality is that manyclinicians approach longevity medicine witha complex mixture of intellectual curiosity,pro